AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2645466
Drug: Immunotherapy (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy (oral bacille Calmette‐Guérin [BCG] 120 mg once a month for 5 years)
Trial: 2645466
Drug: Chemoimmunotherapy (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoimmunotherapy (oral BCG 120 mg once a month for 5 years with meCCNU 130 mg/m2 on day 1 and 5-FU 325 mg/m2/day on days 1-5 and 375 mg/m2/day on days 36-40, repeated every 10 weeks for 8 cycles)
Trial: 2645466
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no further therapy after surgery)
Trial: 28103611
Drug: Cabozantinib 100
RxNorm normalized name: cabozantinib 100 MG Daily Dose Carton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib 100 mg daily during a 12-week lead-in
Trial: 22592176
Drug: Handled medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Handled medicine ball (HMB) throws included in the regular tennis practice
Trial: 21757667
Drug: Intravenous tissue-type
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tissue-type plasminogen activator (tPA) at a total dose of 0.9 mg/kg, with 10% given as a 1-minute bolus and the remainder over 1 hour
Trial: 8508462
Drug: Sabeluzole 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sabeluzole 2 x 10 mg/d
Trial: 8508462
Drug: Sabeluzole 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sabeluzole 3 x 10 mg/d
Trial: 2832178
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus 600 cGy of both upper and lower half-body irradiation
Trial: 21198719
Drug: Amikacin 15
RxNorm normalized name: amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Amikacin 15 mg/kg once per day (group I)
Trial: 21198719
Drug: Amikacin 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amikacin 7.5 mg/kg twice per day (group II)
Trial: 17350868
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids (fluticasone propionate 200 mcg/day by metered dose inhaler/spacer combination)
Trial: 17350868
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids (fluticasone propionate)
Trial: 9351742
Drug: Nitric oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitric oxide inhalation (30 ppm)
Trial: 29071968
Drug: Regular medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular medication and swallowing function rehabilitation training
Trial: 26645524
Drug: Ginger essence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger essence inhalation (2 drops on gauze, repeated every 30 min for 2 hours)
Trial: 26645524
Drug: Ginger essence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger essence inhalation
Trial: 21517667
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMWH), tinzaparin
Trial: 18284511
Drug: 0.05% Clobetasol
RxNorm normalized name: CLOBETASOL PROPIONATE 0.5 mg in 1 g TOPICAL CREAM [Clobetasol Propionate Cream, 0.05% Clobetasol Propionate Cream, 0.05%]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% Clobetasol + 2.5% zinc sulphate cream
Trial: 18284511
Drug: 0.05% Clobetasol
RxNorm normalized name: CLOBETASOL PROPIONATE 0.5 mg in 1 g TOPICAL CREAM [Clobetasol Propionate Cream, 0.05% Clobetasol Propionate Cream, 0.05%]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% Clobetasol alone cream
Trial: 12728112
Drug: Naturopathic Herbal
RxNorm normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naturopathic Herbal Extract Ear Drops (NHED) 5 drops 3 times daily
Trial: 12728112
Drug: Naturopathic Herbal
RxNorm normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naturopathic Herbal Extract Ear Drops (NHED) with topical anesthetic 5 drops 3 times daily
Trial: 12728112
Drug: Topical anesthetic
RxNorm normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical anesthetic 5 drops 3 times daily
Trial: 12728112
Drug: Oral amoxicillin
RxNorm normalized name: amoxicillin Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral amoxicillin 80 mg/kg/d (maximum 500 mg/dose) divided into 3 doses with either NHED or topical anesthetic
Trial: 12940661
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of recombinant tissue plasminogen activator (3 mg in 3 mL diluted into 250 mL of physiological saline solution, given every 12 hours)
Trial: 10553534
Drug: Cilostazol 200
RxNorm normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cilostazol 200 mg/day for 3 months
Trial: 10553534
Drug: Cilostazol 200
RxNorm normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cilostazol 200 mg/day for 6 months
Trial: 29298077
Drug: Gabapentin only
RxNorm normalized name: Gabapentin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin only (900 mg/day)
Trial: 29298077
Drug: Osteopathic Manipulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopathic Manipulative Medicine (OMM) only
Trial: 29078965
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (standardized needle manipulation at LI10 and LI11 for 2 minutes)
Trial: 26144850
Drug: ROM-6 (monthly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ROM-6 (monthly rifampicin, ofloxacin, and minocycline for six months)
Trial: 26144850
Drug: PB-MDT (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PB-MDT (standard World Health Organization paucibacillary multidrug therapy)
Trial: 21695893
Drug: Calcium 440
RxNorm normalized name: calcium carbonate 440 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium 440 mg/d and VD 100 IU/d
Trial: 21695893
Drug: Calcium 440
RxNorm normalized name: calcium carbonate 440 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium 440 mg/d, VD 100 IU/d and soy isoflavone 100 mg/d
Trial: 15333424
Drug: sivelestat (ONO-5046)
RxNorm normalized name: Sivelestat
DrugBank: Sivelestat (DB12863)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: sivelestat (ONO-5046) 0.2 mg/kg/h for 14 days
Trial: 9287061
Drug: Modified Widman
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Widman flap and topical application of saturated citric acid at pH 1 for 3 minutes (CA group)
Trial: 3446303
Drug: Time-limited therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time-limited therapy carried out by trainees
Trial: 29354935
Drug: Auricular point
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auricular point sticking therapy combined with western medicine
Trial: 29354935
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine only (control group)
Trial: 25394430
Drug: Mannitol administration
RxNorm normalized name: Mannitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mannitol administration to kidney donors
Trial: 23697857
Drug: Intravitreal diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal diclofenac (IVD) - 500 μg/0.1 mL
Trial: 23697857
Drug: Intravitreal triamcinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal triamcinolone (IVT) - 2 mg
Trial: 17042147
Drug: Cetirizine hydrochloride
RxNorm normalized name: Cetirizine Hydrochloride
DrugBank: Cetirizine (DB00341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cetirizine hydrochloride (5 mg)‐pseudoephedrine hydrochloride (120 mg) (cetirizine‐D) twice daily
Trial: 14572578
Drug: Etidronate (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etidronate (400 mg/day)
Trial: 23756263
Drug: Transfusion to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfusion to raise haemoglobin to at least 10.0 g/dL
Trial: 19875386
Drug: Gp IIb-IIIa
RxNorm normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gp IIb-IIIa inhibitors
Trial: 16798772
Drug: Ropivacaine 2
RxNorm normalized name: fentanyl-ropivacaine 2 mcg/mL-0.1% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 2 mg h(‐1) (group R, n=22)
Trial: 16798772
Drug: Ropivacaine 1
RxNorm normalized name: ROPivacaine 1% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 1 mg h(‐1) with morphine 8 microg h(‐1) (group RM, n=22)
Trial: 16798772
Drug: Ropivacaine 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 7.5 mg ml(‐1) for continuous spinal anaesthesia
Trial: 12783034
Drug: Ibuprofen (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (1200 mg x d-1)
Trial: 12783034
Drug: Acetaminophen (4000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (4000 mg x d-1)
Trial: 10839900
Drug: CIO (Continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIO (Continuous Insufflation of Oxygen) at a flow rate of 15 l/min
Trial: 26847832
Drug: Active Hexose
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Hexose Correlated Compound (AHCC) 6.0 g for 2 months
Trial: 26847832
Drug: Active Hexose
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Hexose Correlated Compound (AHCC)
Trial: 22354671
Drug: TAP block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAP block with 15 ml 0.25% bupivacaine (group T, n=25)
Trial: 20113315
Drug: Cardi04-300 ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardi04-300 ml
Trial: 20113315
Drug: Cardi04-150 ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardi04-150 ml
Trial: 17030155
Drug: Placebo controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo controlled blood pressure lowering (ACE inhibitor-diuretic combination: perindopril-indapamide)
Trial: 15853986
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with 3 or 5 MU IFN-alpha-2b thrice weekly and oral ribavirin (800-1200 mg/day) for 24 weeks
Trial: 15853986
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with IFN-alpha and ribavirin
Trial: 12030663
Drug: Combined warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined warfarin and aspirin, low doses
Trial: 12030663
Drug: Warfarin alone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin alone, low doses
Trial: 12030663
Drug: Aspirin alone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin alone, low doses
Trial: 1907555
Drug: 1,25-dihydroxyvitamin D3
RxNorm normalized name: 1,25-dihydroxyvitamin D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,25-dihydroxyvitamin D3 ointment (1 microgram g-1) applied topically for 24 hours
Trial: 1907555
Drug: 1,25-dihydroxyvitamin D3
RxNorm normalized name: 1,25-dihydroxyvitamin D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,25-dihydroxyvitamin D3 (10(-8) mol l-1) applied to cultured human keratinocytes for more than 9 days
Trial: 31531421
Drug: Lignocaine liposomal
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignocaine liposomal infusion only
Trial: 31531421
Drug: Lignocaine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignocaine plus epinephrine liposomal infusion
Trial: 14972424
Drug: Aspirin +
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin + Warfarin (1.25mg of warfarin plus 75mg of aspirin)
Trial: 14972424
Drug: Aspirin (75mg)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (75mg)
Trial: 11502526
Drug: Clinafloxacin (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinafloxacin (single oral doses)
Trial: 9210065
Drug: All-trans retinoic
RxNorm normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All-trans retinoic acid (ATRA) with cytosine arabinoside (4 g/course, 1 to 9 courses every 4 weeks)
Trial: 9210065
Drug: Cytosine arabinoside
RxNorm normalized name: Cytosine arabinoside
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cytosine arabinoside (4 g/course, 1 to 9 courses every 4 weeks)
Trial: 19660844
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g of casein
Trial: 19660844
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g of whey protein
Trial: 19660844
Drug: 15 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g of whey protein combined with 5 g of essential amino acids
Trial: 18498918
Drug: Inhibitron (test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhibitron (test formulation)
Trial: 18498918
Drug: LosecA (reference
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LosecA (reference formulation)
Trial: 8763463
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg itraconazole daily for 12 weeks
Trial: 28622082
Drug: Micro-needling combined
RxNorm normalized name: Salicylic Acid 0.002 TOPICAL PATCH [Egg micro needle soothing]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micro-needling combined with 10% TCA cream
Trial: 24679046
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (40 IU) administered twice a day for 7.5 days
Trial: 24679046
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered twice a day for 7.5 days
Trial: 22223814
Drug: Drug company
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Drug company advertisements
Trial: 17656469
Drug: DPC 333
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPC 333 at 5.5 mg/kg daily for 2 weeks in a rat collagen antibody-induced arthritis model
Trial: 17656469
Drug: DPC 333
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPC 333 (oral)
Trial: 17656469
Drug: DPC 333
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPC 333 (oral, single escalating doses)
Trial: 11799030
Drug: Butterbur (carbon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butterbur (carbon dioxide extract tablets, ZE 339) one tablet, four times daily for two weeks
Trial: 11799030
Drug: Cetirizine, one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine, one tablet in the evening for two weeks
Trial: 7658296
Drug: Parents who
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parents who attended evening sessions of the drug prevention program
Trial: 2096106
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg dimethindene maleate (Fenistil, Tropfen)
Trial: 1015353
Drug: Postmyocardial Infarction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postmyocardial Infarction Clinic treatment
Trial: 28926885
Drug: Intense pulsed
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intense pulsed light (IPL) therapy with energy of 14-16 J/cm²
Trial: 28926885
Drug: Control eye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control eye receiving placebo therapy with 0 J/cm²
Trial: 16807281
Drug: Oral HRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral HRT (conjugated equine estrogen 0.625 mg/day for 6 months)
Trial: 16807281
Drug: Transdermal HRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal HRT (17beta‐estradiol gel 0.6 mg/day for 6 months)
Trial: 12891248
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with fluvastatin (40 mg/day) and fenofibrate (200 mg/day)
Trial: 1549214
Drug: Deprenyl (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deprenyl (10 mg/d)
Trial: 26983055
Drug: Indirect moxibustion
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indirect moxibustion therapy
Trial: 24565387
Drug: Intravenous clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous clonidine (2 μg/kg)
Trial: 20435194
Drug: Tolvaptan (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolvaptan (oral vasopressin receptor antagonist)
Trial: 11876714
Drug: Bifidobacterium animalis
RxNorm normalized name: Bifidobacterium Animalis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifidobacterium animalis DN-173 010 (three 125 g cups per day of fermented milk)
Trial: 8525285
Drug: 400 micrograms/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 micrograms/kg with a clearing dose
Trial: 8525285
Drug: 400 micrograms/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 micrograms/kg without a clearing dose
Trial: 8525285
Drug: 600 micrograms/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 micrograms/kg with a clearing dose
Trial: 8525285
Drug: 600 micrograms/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 micrograms/kg without a clearing dose
Trial: 8525285
Drug: 800 micrograms/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 micrograms/kg with a clearing dose
Trial: 8525285
Drug: 800 micrograms/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 micrograms/kg without a clearing dose
Trial: 2145407
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment for elderly patients with grade III or IV retinopathy, congestive heart failure, or cerebral infarction or hemorrhage.
Trial: 2145407
Drug: Non-pharmacological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-pharmacological treatment for elderly patients with established mild hypertension under 80 years of age.
Trial: 2145407
Drug: Pharmacologic antihypertensive
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacologic antihypertensive treatment for elderly patients over 80 years of age or those with isolated systolic hypertension.
Trial: 394868
Drug: CAMP chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAMP chemotherapy
Trial: 394868
Drug: CCNU as
RxNorm normalized name: Lomustine
DrugBank: Lomustine (DB01206)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CCNU as a single agent
Trial: 30734357
Drug: Intraluminal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraluminal therapy for H. pylori infection (ILTHPI)
Trial: 22091267
Drug: Nasal beclomethasone
RxNorm normalized name: beclomethasone Nasal Spray
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal beclomethasone spray
Trial: 22091267
Drug: Amoxicillin and
RxNorm normalized name: omeprazole, amoxicillin and rifabutin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin and decongestant (control group)
Trial: 19782925
Drug: Daily walking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily walking distance measured by pedometer over one week
Trial: 14687321
Drug: Comprehensive review
RxNorm normalized name: Easy Care First Aid Kit - Comprehensive KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive review and recommended modification of a patient's medication regimen
Trial: 7965276
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (diuretic, beta-blocker or both)
Trial: 31856942
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (standard NHS care for depression)
Trial: 29307330
Drug: Inulin-type fructan
RxNorm normalized name: Inulin
DrugBank: Inulin (DB00638)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Inulin-type fructan prebiotic (Orafti® Synergy 1; 16 g/d)
Trial: 29307330
Drug: Placebo (Glucidex®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Glucidex® 29 Premium; 16 g/d)
Trial: 11792139
Drug: Eptifibatide (glycoprotein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eptifibatide (glycoprotein IIb/IIIa inhibitor)
Trial: 10579750
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II antagonists at initial doses
Trial: 10579750
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II antagonists at doubled doses
Trial: 10579750
Drug: Hydrochlorothiazide 12.5
RxNorm normalized name: hydrochlorothiazide 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 12.5 mg daily added to initial doses of angiotensin II antagonists
Trial: 2346518
Drug: Long-acting ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting ibuprofen (2,400 mg/day)